CTOs on the Move

Newport Healthcare

www.newporthealthcare.com

 
Newport Healthcare is changing the face of behavioral health services for teens, young adults and their families by providing sustainable healing.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).

Ironshore Pharmaceuticals

Ironshore Therapeutics Inc. (formerly known as Highland Therapeutics Inc.) is a pharmaceutical company whose mission is to develop and commercialize first-in-class treatment options to improve the lives of patients and caregivers.

Brains Bioceutical

Brains Bioceutical Corp is a globally recognized leader in GMP-certified production of naturally-sourced Active Pharmaceutical Ingredients (API).

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.

THE PLANNING SHOP International

THE PLANNING SHOP International is a Jamison, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.